FDA warns GSK on manufacturing practices at Canada plant

June 24, 2014 3:08 PM

3 0

WASHINGTON, June 24 (Reuters) - The U.S. Food and Drug Administration has warned GlaxoSmithKline Plc that one of its plants in Canada violated quality control standards during the manufacture of its influenza vaccine Flulaval.

In a warning letter dated June 12, the FDA said the company had failed to take appropriate steps to prevent microbiological contamination of drugs, among other violations.

Read more

To category page